文献速递流行病学与生物统计基础与转化研究真实世界研究与卫生经济

肺癌治疗进展对人群死亡率的影响

The Effect of Advances in Lung-Cancer Treatment on Population Mortality.
PubMed 文献 · N Engl J Med · 2020-01-01

该研究利用SEER数据评估肺癌亚型的人群死亡率趋势,发现2013至2016年非小细胞肺癌死亡率下降快于发病率,且生存改善与靶向治疗获批时间吻合;小细胞肺癌死亡率下降主要因发病率降低,生存无改善。

要点

  • NSCLC死亡率下降与靶向治疗获批时间相关,生存率改善。
  • 男性NSCLC发病率死亡率均下降,生存率从26%升至35%。
  • SCLC死亡率下降主要因发病率降低,生存无改善。

核心结论

  • 美国NSCLC人群死亡率在2013至2016年大幅下降,诊断后生存率显著改善。
  • 发病率降低与治疗进展(尤其靶向治疗获批和使用)可能解释该时期死亡率下降。

研究设计与样本

  • 基于SEER登记处数据,评估肺癌死亡率并将肺癌死亡与发病病例链接。
  • 评估特定亚型的发病率基础死亡率,以及按亚型、性别和日历年分的发病率和生存率。

主要发现

  • 男性NSCLC发病率基础死亡率从2013到2016年每年下降6.3%,发病率从2008到2016年每年下降3.1%。
  • 男性NSCLC肺癌特异性生存率从2001年诊断的26%改善到2014年诊断的35%。
  • SCLC死亡率下降几乎完全因发病率下降,生存无改善。

临床怎么用

  • 关注NSCLC靶向治疗的应用以改善生存。
  • SCLC需更多治疗进展以改善生存。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Lung cancer is made up of distinct subtypes, including non-small-cell lung cancer (NSCLC) and small-cell lung cancer (SCLC). Although overall mortality from lung cancer has been declining in the United States, little is known about mortality trends according to cancer subtype at the population level because death certificates do not record subtype information. METHODS: Using data from Surveillance, Epidemiology, and End Results (SEER) areas, we assessed lung-cancer mortality and linked deaths from lung cancer to incident cases in SEER cancer registries. This allowed us to evaluate population-level mortality trends attributed to specific subtypes (incidence-based mortality). We also evaluated lung-cancer incidence and survival according to cancer subtype, sex, and calendar year. Joinpoint software was used to assess changes in incidence and trends in incidence-based mortality. RESULTS: Mortality from NSCLC decreased even faster than the incidence of this subtype, and this decrease was associated with a substantial improvement in survival over time that corresponded to the timing of approval of targeted therapy. Among men, incidence-based mortality from NSCLC decreased 6.3% annually from 2013 through 2016, whereas the incidence decreased 3.1% annually from 2008 through 2016. Corresponding lung cancer-specific survival improved from 26% among men with NSCLC that was diagnosed in 2001 to 35% among those in whom it was diagnosed in 2014. This improvement in survival was found across all races and ethnic groups. Similar patterns were found among women with NSCLC. In contrast, mortality from SCLC declined almost entirely as a result of declining incidence, with no improvement in survival. This result correlates with limited treatment advances for SCLC in the time frame we examined. CONCLUSIONS: Population-level mortality from NSCLC in the United States fell sharply from 2013 to 2016, and survival after diagnosis improved substantially. Our analysis suggests that a reduction in incidence along with treatment advances - particularly approvals for and use of targeted therapies - is likely to explain the reduction in mortality observed during this period.

来源:N Engl J Med,查看原文。版权归原作者所有。

引用

  1. Howlader N, Forjaz G, Mooradian MJ, et al. The Effect of Advances in Lung-Cancer Treatment on Population Mortality. N Engl J Med. 2020. PMID: 32786189. doi:10.1056/NEJMoa1916623

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。